CVS Health (CVS)
(Delayed Data from NYSE)
$66.63 USD
-0.22 (-0.33%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $66.63 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
A Value D Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$66.63 USD
-0.22 (-0.33%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $66.63 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
A Value D Growth C Momentum B VGM
Zacks News
Cigna (CI) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Cigna's (CI) Q2 earnings should reflect increase in revenues from growth across its segments and share buyback.
CVS Health (CVS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, CVS Health (CVS) closed at $56.26, marking a +1.3% move from the previous day.
Is Deep Value ETF (DVP) a Strong ETF Right Now?
by Sweta Killa
Smart Beta ETF report for DVP
CVS Health (CVS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, CVS Health (CVS) closed at $55.47, marking a -0.84% move from the previous day.
CVS Health (CVS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, CVS Health (CVS) closed at $57.44, marking a -0.19% move from the previous day.
ETFs to Shine as Trump Tosses Drug Rebate Curb Plan
by Sweta Jaiswal, FRM
We study the impact of Trump's dropping of the proposed drug rebate rule on some health ETFs with exposure to pharmacy benefit managers and healthcare insurers.
The Zacks Analyst Blog Highlights: DaVita, Fresenius, Baxter, Amgen and CVS
by Zacks Equity Research
The Zacks Analyst Blog Highlights: DaVita, Fresenius, Baxter, Amgen and CVS
Stock Market News for Jul 12, 2019
by Zacks Equity Research
The Dow and S&P 500 closed at record highs on Thursday riding a rally among healthcare shares and Fed???s indication of an easier monetary policy.
Trump Drops Drug Rebate Proposal: What's Next and What Stocks to Play
by Christopher Vargas
The Trump administration announced Thursday that it's deciding to withdraw its proposal to eliminate rebates from government drug plans.
Can CVS Health (CVS) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
CVS Health (CVS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Trump's Order on Kidney Care Lifts These Dialysis Stocks
by Tirthankar Chakraborty
Dialysis stocks move north after Trump signs an executive order designed to reform the nation's kidney treatment industry.
CVS Health (CVS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed at $54.83 in the latest trading session, marking a -0.87% move from the prior day.
CVS Health Banks on Aetna Prospects, Omnicare May Disappoint
by Zacks Equity Research
CVS Health's (CVS) Aetna integration synergies bode well for the stock.
Here's Why CVS Health (CVS) Should Be in Your Portfolio
by Zacks Equity Research
Investors' trust continues to be high in CVS Health (CVS), thanks to strength in its PBM business.
Top Analyst Reports: Mastercard, Coca-Cola, Amgen & More
by Kalyan Nandy
Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), Coca-Cola (KO) and Amgen (AMGN).
CVS Health (CVS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, CVS Health (CVS) closed at $54.80, marking a -0.24% move from the previous day.
Is Deep Value ETF (DVP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DVP
Will Amazon (AMZN) be Rite-Aid's (RAD) Bandage?
by Mitchell Moore
Rite Aid Corporation (RAD) posted its Q1 2020 earnings results on Wednesday, June 26, after market close. This report was disappointing with an adjusted loss of -$0.14 per share, a steep dive from our zacks Consensus Estimate of +$0.02.
The Zacks Analyst Blog Highlights: Merck, Tractor Supply, IDEXX and CVS
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Tractor Supply, IDEXX and CVS
CVS Health (CVS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, CVS Health (CVS) closed at $53.70, marking a +0.04% move from the previous day.
4 Stocks to Make the Most of the Growing Love for Pets
by Tirthankar Chakraborty
With the U.S. pet industry poised to grow 3.9% to a record $75.4 billion this year, here are few stocks that could gain from the growing love for animals.
Tenet Healthcare Inks Deal to Offer Quality Health Services
by Zacks Equity Research
Tenet Healthcare (THC) enters into a contract with Aetna owing to which the company's healthcare services can be availed by Aetna members.
CVS Health (CVS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed at $53.87 in the latest trading session, marking a -1.86% move from the prior day.
Is Deep Value ETF (DVP) a Strong ETF Right Now?
by Sweta Killa
Smart Beta ETF report for DVP
Do Hemp Stocks Stand to Gain From a Weed-Liberal Illinois?
by Nitish Marwah
The marijuana legislation in Illinois would allow any resident of the state above the age of 21 to possess the novelty item.